Prokidney LLC

ProKidney is a leading biotechnology clinic dedicated to transforming the landscape of chronic kidney disease (CKD) treatment through innovative therapies. With a focus on preserving kidney function in patients at high risk of kidney failure, the clinic is currently conducting the pivotal Phase 3 clinical study known as PROACT 1. This groundbreaking research centers around Rilparencel, a first-in-class autologous cell therapy designed to utilize the patient's own kidney cells to delay or potentially prevent the progression to dialysis. This unique approach not only minimizes the need for immunosuppressive therapy but also aims to tap into the innate repair mechanisms of the kidneys, offering hope to the millions affected by advanced CKD. ProKidney's commitment to addressing the significant unmet medical needs in the realm of kidney disease is evident through its advanced clinical pipeline and emphasis on patient-centered care. Over 35 million adults in the U.S. live with CKD, and the clinic recognizes the urgency of providing effective therapeutic options for this population. By focusing on the safety and efficacy of Rilparencel, which has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, ProKidney stands at the forefront of kidney disease management. Its innovative solutions not only aim to preserve kidney function but also enhance the quality of life for patients navigating the complexities of chronic kidney disease.